Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailAntigone et Manon s’invitent en droit social. Quelques propos sur la légalité de la preuve
Kefer, Fabienne ULg

in Revue Critique de Jurisprudence Belge (2009), 3

Detailed reference viewed: 254 (34 ULg)
See detailAntigone image de la limite: habiter le seuil du représentable chez Judith Butler
Borotto, Jessica ULg

Scientific conference (2014, December 08)

Detailed reference viewed: 19 (1 ULg)
See detail« Antigone » en droit fiscal : quelle évolution ?
Bourgeois, Marc ULg; Verscheure, Céline ULg

in Bourgeois, Marc; Verscheure, Céline; Herbecq, François (Eds.) et al Le droit fiscal en 2017 : questions choisies (2017)

Detailed reference viewed: 34 (4 ULg)
See detailAntigone, Médée. Figures de subversion
Borotto, Jessica ULg

Conference given outside the academic context (2016)

Detailed reference viewed: 16 (0 ULg)
Peer Reviewed
See detailAntihyperglycaemic agents. Drug interactions of clinical importance.
Scheen, André ULg; Lefebvre, Pierre ULg

in Drug Safety : An International Journal of Medical Toxicology & Drug Experience (1995), 12(1), 32-45

Non-insulin-dependent (type 2) diabetes mellitus (NIDDM) affects middle-aged or elderly people who frequently have several other concomitant diseases, especially obesity, hypertension, dyslipidaemias ... [more ▼]

Non-insulin-dependent (type 2) diabetes mellitus (NIDDM) affects middle-aged or elderly people who frequently have several other concomitant diseases, especially obesity, hypertension, dyslipidaemias, coronary insufficiency, heart failure and arthropathies. Thus, polymedication is the rule in this population, and the risk of drug interactions is important, particularly in elderly patients. The present review is restricted to the interactions of other drugs with antihyperglycaemic compounds, and will not consider the mirror image, i.e. the interactions of antihyperglycaemic agents with other drugs. Oral antihyperglycaemic agents include sulphonylureas, biguanides--essentially metformin since the withdrawn of phenformin and buformin--and alpha-glucosidase inhibitors, acarbose being the only representative on the market. These drugs can be used alone or in combination to obtain better metabolic control, sometimes with insulin. Drug interactions with antihyperglycaemic agents can be divided into pharmacokinetic and pharmacodynamic interactions. Most pharmacokinetic studies concern sulphonylureas, whose action may be enhanced by numerous other drugs, thus increasing the risk of hypoglycaemia. Such an effect may result essentially from protein binding displacement, inhibition of hepatic metabolism and reduction of renal clearance. Reduction of the hypoglycaemic activity of sulphonylureas due to pharmacokinetic interactions with other drugs appears to be much less frequent. Drug interactions leading to an increase in plasma metformin concentrations, mainly by reducing the renal excretion or the hepatic metabolism of the biguanide, should be avoided to limit the risk of hyperlactaemia. Owing to its mode of action, pharmacokinetic interferences with acarbose are limited to the gastrointestinal tract, but have not been extensively studied yet. Pharmacodynamic interactions are quite numerous and may result in a potentiation of the hypoglycaemic action or, conversely, in a deterioration of blood glucose control. Such interactions may be observed whatever the type of antidiabetic treatment. They result from the intrinsic properties of the coprescribed drug on insulin secretion and action, or on a key step of carbohydrate metabolism. Finally, a combination of 2 to 3 antihyperglycaemic agents is common for treating patients with NIDDM to benefit from the synergistic effect of compounds acting on different sites of carbohydrate metabolism. Possible pharmacokinetic interactions between alpha-glucosidase inhibitors and classical antidiabetic oral agents should be better studied in the diabetic population. [less ▲]

Detailed reference viewed: 48 (0 ULg)
Full Text
Peer Reviewed
See detailAntihyperglycémiants, antihypertenseurs et hypolipidémiants : comparaison des effets sur la mortalité et la morbidité cardiovasculaire chez le patient diabétique de type 2
SCHEEN, André ULg

Poster (2016, March)

Introduction : Réduire le risque de mortalité et morbidité cardiovasculaire (CV) chez le patient diabétique de type 2 (DT2) est primordial, mais les effets protecteurs semblent différents selon le mode ... [more ▼]

Introduction : Réduire le risque de mortalité et morbidité cardiovasculaire (CV) chez le patient diabétique de type 2 (DT2) est primordial, mais les effets protecteurs semblent différents selon le mode d’intervention pharmacologique étudié. Patients et méthodes : Les données de mortalité (totale et CV) et morbidité (infarctus du myocarde ou IDM, accidents vasculaires cérébraux ou AVC) rapportées (réduction du risque relatif) dans les essais ayant testé un traitement anti-hyperglycémiant sont comparées avec les résultats publiés dans deux méta-analyses concernant les hypolipidémiants et les anti-hypertenseurs consacrées au DT2. Résultats : Les antihypertenseurs réduisent les IDM (-12%) et la mortalité globale (-13%) de façon comparable, et diminuent davantage les AVC (-27%). Les hypolipidémiants diminuent davantage les IDM (- 22%) et les AVC (-21%) que la mortalité globale (-9%) (ou la mortalité CV : - 13%). Les données concernant les antihyperglycémiants diffèrent considérablement selon les médications testées. L’insuline et les sulfamides (UKPDS) réduisent plus les IDM (- 21%) que la mortalité totale (-8%), mais augmentent les AVC (+ 14%). La metformine (UKPDS) réduit, de façon comparable, les IDM (-39%), les AVC (-41%) et la mortalité totale (-36%). La pioglitazone (PROactive) diminue davantage les IDM (-17%) et les AVC (-19%) que la mortalité (-4%). Les gliptines (combinaison de SAVOR TIMI 53, EXAMINE, TECOS) ont montré des effets globalement neutres sur la mortalité totale (0%), les IDM (-2%) et les AVC (-1%). L’empagliflozine (EMPA-REG OUTCOME) se singularise par un effet favorable nettement plus marqué sur la mortalité totale (-32 %) et CV (- 38%) que sur les IDM (-13%) ou les AVC (+18%). Conclusion : Les discordances observées suggèrent l’implication de mécanismes protecteurs différents selon les interventions testées. EMPA-REG OUTCOME, le seul essai démontrant un effet plus marqué sur la mortalité que sur les événements CV, suggère un mécanisme propre de l’inhibiteur des SGLT2. [less ▲]

Detailed reference viewed: 56 (1 ULg)
See detailAntihypertenseur et AVC - de la prévention au traitement
Krzesinski, Jean-Marie ULg

Conference (2004, March 15)

Detailed reference viewed: 50 (14 ULg)
Full Text
Peer Reviewed
See detailAntihypertensive and vasorelaxant effects of aqueous extract of Artemisia campestris L. from Eastern Morocco.
Dib, Ikram; Tits, Monique ULg; Angenot, Luc ULg et al

in Journal of Ethnopharmacology (2017), 206

ETHNOPHARMACOLOGICAL RELEVANCE: Artemisia campestris L. (Asteraceae) has many traditional uses, among which treatment of diabetes and hypertension. AIM OF THE STUDY: This study was conducted in order to ... [more ▼]

ETHNOPHARMACOLOGICAL RELEVANCE: Artemisia campestris L. (Asteraceae) has many traditional uses, among which treatment of diabetes and hypertension. AIM OF THE STUDY: This study was conducted in order to confirm the antihypertensive and hypotensive effects of A. campestris L. aqueous extract (AcAE) and to explore the underlying mechanism of action of its vasorelaxant effect, besides the acute toxicity. Also, the chemical composition of AcAE was investigated. MATERIAL AND METHODS: the chemical content of AcAE was determined by using HPLC and NMR techniques. The antihypertensive effect was assessed indirectly by tail-cuff method on L-NAME induced hypertensive rats, while the hypotensive action was monitored intravenously by invasive method on normotensive rats. The vasorelaxant effect and vascular mechanism of action were studied in the presence of antagonists and blockers on aorta isolated from normotensive rats. On the other side, the acute toxicity was studied by oral feeding of extract to the mice. RESULTS: The global phytochemical profile of AcAE reveals the presence of several polyphenols as main components. A. campestris L. infusion was characterized by mono- and di-cinnamoyl compounds, with 3,5-dicaffeoylquinic (isochlorogenic A) acid being the main compound, followed by 5-caffeoylquinic (chlorogenic) acid. Vicenin-2 (apigenin 6,8-di-C-glucoside) appeared to be the most abundant compound among flavonoids. The daily treatment with AcAE at 150mg/Kg/day prevented the installation of hypertension on L-NAME hypertensive rats, and reduced SBP from 172mmHg up to 144mmHg. At the dose 40mg/Kg, AcAE provoked reduction of systolic (SBP), diastolic (DBP) and mean arterial pressure (MAP), without affecting the heart rate. Also, AcAE (10-2-2mg/ml) relaxed the precontracted aorta by 95.8 +/- 1.3%. The denudation and preincubation of aorta with atropine, calmidazolium, L-NAME, hydroxycobalamin, ODQ, 8-RP-Br-PET-cGMP, thapsigargin and verapamil attenuated the vasorelaxant response, while the pre-treatment with 4-AP, TEA, glibenclamide and BaCl2 did not alter this effect. The oral administration of AcAE (0-6g/Kg) reveals no mortality or toxicity. CONCLUSIONS: our study proved that AcAE possess an important antihypertensive, hypotensive and vasorelaxant effect, which is mediated via calmodulin-NO-cGC-PKG pathway, and via inhibition of calcium influx through voltage-operated calcium channels and activation of intracellular calcium mobilization into sarcoplasmic reticulum. Therefore, our findings give first evidence about the traditional use of A. campestris L. as antihypertensive plant. [less ▲]

Detailed reference viewed: 55 (3 ULg)
Full Text
Peer Reviewed
See detailAntihypertensive therapy and blood pressure control in renal transplant recipients.
Saint-Remy, Annie ULg; Ait Oile, Fatima; Weekers, Laurent ULg et al

in American Journal of Hypertension : Journal of the American Society of Hypertension (2004), 17(5), 122-123

Renal transplant recipients are at high risk of cardiovascular diseases which represent,with infections, their major cause of excessive deaths. Immunosuppressive treatments are partly responsible leading ... [more ▼]

Renal transplant recipients are at high risk of cardiovascular diseases which represent,with infections, their major cause of excessive deaths. Immunosuppressive treatments are partly responsible leading to hypertension (HT), diabetes and hyperlipidemia. Aim: This study analyses the blood pressure (BP) control in renal transplant recipients with functioning graft according to their current antihypertensive and immunosuppressive therapies. Data were collected for 211 patients (M:58%; F:42%) transplanted on average since 7.7 years (2-360 months). Mean age was 50 years (16–72), 84% had hypercholesterolemia (>1.9 g/l), 18% were diabetics and 24% were smokers. Seventy-eight % were under antihypertensive treatment. Results: HT (mean OBP of 3 visits: >140 and/or >90 mmHg or treated) was observed in half of the untreated patients and uncontrolled in 80% of the treated ones. Ninety % of the treated hypertensive diabetic patients didn't reach target BP <130/80 mmHg. HT was significantly more frequent in patients whose glomerular filtration(GFR) was lower than the median value of GFR (55 ml/min/1.73 m2) of the population. Among treated patients, 48% had 1 drug, 29% had 2 drugs and 23% had 3 drugs or more. Beta-Blockers were the most prescribed even in association, while diuretics were less used since, even in 3 drugs therapy, only 60% received such class. Calcium inhibitors were not prescribed readily in first line but accounted for 47% in 2 drugs combinations. These observations were not related to the GFR level. Only 26% received an ACE inhibitor, their prescription decreases roughly in patients with impaired GFR. AII-RB concerned only 10% of therapies. Body weight, creatinine, graft survival and recipient's age were significantly related to SBP and DBP. In patients treated with cyclosporin, a highly significant relation (p=0.02) was found between BP and blood level of CsA, this was not observed in patients treated with tacrolimus . Conclusion: HT was highly prevalent in renal transplant recipients( 88% of patients) even when treated. This study leads to reconsider habits of prescrition in view to improve the BP control by increasing the use of diuretics and to improve cardioprotection by using more often ACE inhibitors (when not contra-indicated) in that high cardiovascular risk population. As mentioned in literature, the effect of tacrolimus on BP appears lesser than the cyclosporine one. [less ▲]

Detailed reference viewed: 29 (2 ULg)
Full Text
Peer Reviewed
See detailAntiinflammatory activity of Centaurea cyanus flowers
Bodart, Patricia; Damas, Jacques ULg; Goldsztajn, V. et al

in Journal de Pharmacie de Belgique (1994, February), 59(1), 73

Detailed reference viewed: 27 (1 ULg)
Full Text
Peer Reviewed
See detailAntiinflammatory activity of centaurea cyanus flowers
Bodart, Patricia; Goldsztajn, V.; Tits, Monique ULg et al

Poster (1994, March)

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailAntiinflammatory and chonroprotective activity of prodelphinidins isolated from Ribes nigrum leaves
Tits, Monique ULg; de Leval Xavier; Dierckxsens, Yvan et al

Poster (2000, July)

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailAntiinflammatory Prodelphinidins from Black Currant (Ribes nigrum) Leaves
Tits, Monique ULg; Angenot, Luc ULg; Damas, Jacques ULg et al

in Planta Medica (1991), 57(Supplement issue 2), 134

In a study to select anti-inflammatory medicinal plants, we have observed that extracts of Ribes nigrum significantly inhibited at a dose of 50mg/kg i.p. the carrageenan rat paw edema. We have now proved ... [more ▼]

In a study to select anti-inflammatory medicinal plants, we have observed that extracts of Ribes nigrum significantly inhibited at a dose of 50mg/kg i.p. the carrageenan rat paw edema. We have now proved that the most active fractions contained proanthocyanidins . In the present study, we report on the isolation of three bioactive compounds: two prodelphinidins dimers and a new trimeric one. [less ▲]

Detailed reference viewed: 155 (4 ULg)
Full Text
Peer Reviewed
See detailAntilisterial Activity on Poultry Meat of Amylolysin, a Bacteriocin from Bacillus amyloliquefaciens GA1
Halimi, Badre Eddine ULg; Dortu, Carine; Arguelles Arias, Anthony ULg et al

in Probiotics and Antimicrobial Proteins (2010)

Detailed reference viewed: 253 (44 ULg)
Full Text
Peer Reviewed
See detailAntilisterial Bacteriocin-Producing Strain Of Lactobacillus Curvatus Cwbi-B28 As A Preservative Culture In Bacon Meat And Influence Of Fat And Nitrites On Bacteriocins Production And Activity
Ghalfi, H.; Kouakou, P.; Duroy, M. et al

in Food Science and Technology International (2006), 12(4),

Detailed reference viewed: 37 (5 ULg)
See detailLes antilopes
Vermeulen, Cédric ULg

in Delvingt, W.; Vermeulen, Cédric (Eds.) Nazinga (2007)

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailAntimalarial Activities of Alkyl Cyclohexenone Derivatives Isolated from the Leaves of Poupartia borbonica
Ledoux, Allison ULg; St-Gelais, Alexis; Cieckiewicz, Ewa ULg et al

in Journal of Natural Products (2017), 80(6), 1750-1757

Bioactivity-guided fractionation of the ethyl acetate extract of the leaves of Poupartia borbonica led to the isolation of three new alkyl cyclohexenone derivatives 1−3, and named Poupartone A−C. The ... [more ▼]

Bioactivity-guided fractionation of the ethyl acetate extract of the leaves of Poupartia borbonica led to the isolation of three new alkyl cyclohexenone derivatives 1−3, and named Poupartone A−C. The structures of the new compounds were elucidated by 1D and 2D NMR spectroscopic data analysis and MS, whereas calculated and experimental ECD spectra were used to define the absolute configurations. These compounds were active against 3D7 and W2 Plasmodium falciparum strains with IC50 values between 0.55 and 1.81 μM. In vitro cytotoxicity against WI38 human fibroblasts and the human cervical cancer cell line HeLa (WST-1 assay) showed that these compounds were also cytotoxic, but no hemolytic activity was observed for the extract and pure compounds. An in vivo antimalarial assay was performed on the major cyclohexenone using P. berghei-infected mice at a dose of 15 mg/kg/day ip. The assay revealed growth inhibition of 59.1 and 69.5% at days 5 and 7 postinfection, respectively, although some toxicity was observed. Zebrafish larvae were used as a model to determine the type of toxicity, and the results showed cardiac toxicity. The methanol extract was also studied, and it displayed moderate antiplasmodial properties in vitro. This extract contained the known flavonoids, quercetin, 3′-O-hydroxysulfonylquercetin, quercitrin, and isoquercitrin as well as ellagic acid, which showed high to low activity against the 3D7 P. falciparum strain. [less ▲]

Detailed reference viewed: 22 (11 ULg)
Full Text
Peer Reviewed
See detailAntimalarial Activity of Cryptolepine and some otrher Anhydronium Bases
Wright, C. W.; Phillipson, J. D.; Awe, S. O. et al

in Phytotherapy Research (1996), 10

Eight naturally occurring anhydronium bases and the synthetic quaternary compound Nb-methylharmalane were tested against Plasmodium falciparun (strain K1) in vitro. Cryptolepine was found to have similar ... [more ▼]

Eight naturally occurring anhydronium bases and the synthetic quaternary compound Nb-methylharmalane were tested against Plasmodium falciparun (strain K1) in vitro. Cryptolepine was found to have similar activity to that of chloroquine but alstonine, 5,6-dihydroflavopereirine, matadine, Nb-methylharmalane, melinonine F, normelinonine F, strychnoxanthine and serpentine were found to have little activity. Cryptolepine, given orally to mice infected with Plasmodium berghei berghei was found to have moderate antimalarial activity; parasitemia was suppressed by 80% at 50 mg/kg/day. [less ▲]

Detailed reference viewed: 34 (3 ULg)
Full Text
Peer Reviewed
See detailAntimalarial compounds isolated from plants used in traditional medicine.
Bero, Joanne; Frederich, Michel ULg; Quetin-Leclercq, Joelle

in Journal of Pharmacy & Pharmacology (2009), 61(11), 1401-33

OBJECTIVES: This review covers the compounds with antiplasmodial activity isolated from plants published from 2005 to the end of 2008, organized according to their phytochemical classes. Details are given ... [more ▼]

OBJECTIVES: This review covers the compounds with antiplasmodial activity isolated from plants published from 2005 to the end of 2008, organized according to their phytochemical classes. Details are given for substances with IC50 values < or = 11 microm. KEY FINDINGS: Malaria is a major parasitic disease in many tropical and subtropical regions and is responsible for more than 1 million deaths each year in Africa. The rapid spread of resistance encourages the search for new active compounds. Nature and particularly plants used in traditional medicine are a potential source of new antimalarial drugs as they contain molecules with a great variety of structures and pharmacological activities. SUMMARY: A large number of antimalarial compounds with a wide variety of structures have been isolated from plants and can play a role in the development of new antimalarial drugs. Ethnopharmacological approaches appear to be a promising way to find plant metabolites that could be used as templates for designing new derivatives with improved properties. [less ▲]

Detailed reference viewed: 129 (6 ULg)